Concepedia

T. Wyant

TW

Statistics

Publications

3

Citations

94

H-Index

3

Active since

2010

Affiliations

Florida Cancer Specialists & Research Institute(Current)

T. Wyant is an author at Florida Cancer Specialists & Research Institute specializing in oncology, molecular oncology, and cancer therapeutics.

Top concepts

Publications per year

2010–2017

3

Publications

3

Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas.

James J. Lee, John D. Powderly, Manish R. Patel et al. · Journal of Clinical Oncology · 2017 · 44 citations

, , +19

Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study.

Suzanne F. Jones, Richard B. Cohen, J. C. Bendell et al. · Journal of Clinical Oncology · 2010 · 27 citations

, , +21

DOP058 Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies

M. Rosario, T. Wyant, Catherine Milch et al. · Journal of Crohn s and Colitis · 2014 · 23 citations · Full text

1–3 of 3